For the Inventor, By the Inventor

Enter assignee name

Gyeonggi-do, South Korea

Olix Pharmaceuticals, Inc.

USPTO Granted Patents = 15

CIPO Patents = 1

EPO Patents = 5

Trademarks = 1

Forward Citations = 41

Loading Chart...

Loading Chart...

16 inventors (with patents filed for the assignee):

Sun Woo Hong (12 out of 12 patents)

Dong Ki Lee (8 out of 16 patents)

Isu Hong (4 out of 4 patents)

4. Ji Hyun Kim (4 out of 129 patents)

5. Hanna Lee (3 out of 11 patents)

6. Ji Eom (3 out of 3 patents)

7. Dayeon Yu (3 out of 3 patents)

8. Jihye Hwang (3 out of 4 patents)

9. Tae Yeon Lee (3 out of 3 patents)

10. Dong-Ki Lee (2 out of 29 patents)

11. Yu Ran Na (2 out of 2 patents)

12. Young-Dong Kim (2 out of 2 patents)

13. Sae-Lo-Oom Lee (2 out of 2 patents)

14. Yang Hee Kim (1 out of 22 patents)

15. Da Seul Son (1 out of 1 patent)

15 patents: Sort by Forward Citations

1. 11591600 - Long double-stranded RNA for RNA interference (2023-02-28),

2. 11118184 - Asymmetric siRNA for inhibiting expression of male pattern hair loss target gene (2021-09-14),

3. 11040057 - Pharmaceutical compositions and methods for potentiating gene silencing (2021-06-22),

4. 10947541 - Treatment of atopic dermatitis and asthma using RNA complexes that target IL4Rα, TRPA1, or F2RL1 (2021-03-16),

5. 10883105 - RNA-interference-inducing nucleic acid molecule able to penetrate into cells, and use therefor (2021-01-05),

6. 10829761 - Treatment of idiopathic pulmonary fibrosis using RNA complexes that target connective tissue growth factor (2020-11-10),

7. 10829760 - Nucleic acid molecules inducing RNA interference, and uses thereof (2020-11-10),

8. 10590423 - Treatment of age-related macular degeneration using RNA complexes that target MyD88 or TLR3 (2020-03-17),

9. 10519449 - Treatment of angiogenesis-associated diseases using RNA complexes that target ANGPT2 and PDGFB (2019-12-31),

10. 10512600 - RNA complexes that inhibit melanin production (2019-12-24),

11. 10358648 - Treatment of atopic dermatitis and asthma using RNA complexes that target IL4Rα, TRPA1, or F2RL1 (2019-07-23),

12. 10301628 - Treatment of idiopathic pulmonary fibrosis using RNA complexes that target connective tissue growth factor (2019-05-28),

13. 10125362 - RNA-interference-inducing nucleic acid molecule able to penetrate into cells, and use therefor (2018-11-13),

14. 10064801 - RNA complexes that inhibit melanin production (2018-09-04),

15. 10059949 - Treatment of age-related macular degeneration using RNA complexes that target MYD88 or TLR3 (2018-08-28),

OLIX PHARMACEUTICALS, INC. is a pharmaceutical company dedicated to improving global health and quality of life. We specialize in the research, development, and commercialization of innovative and effective drugs. With a focus on cutting-edge therapies, we strive to address unmet medical needs and provide patients with more advanced treatment options. Our mission is to make a positive impact on society through the advancement of pharmaceutical sciences.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

15 Patents

#59 in Gyeonggi-do

#737 in South Korea

#38,722 in the World

Gyeonggi-do, South Korea

Olix Pharmaceuticals, Inc.

Forward Citations = 41

16 inventors:

Sun Woo Hong (12 out of 12 patents)

Dong Ki Lee (8 out of 16 patents)

Isu Hong (4 out of 4 patents)

4. Ji Hyun Kim (4 out of 129 patents)

5. Hanna Lee (3 out of 11 patents)

Please report any incorrect information to support@idiyas.com

Loading…